Manufacturers: Arrowhead Pharmaceuticals
Plozasiran (REDEMPLO) is an siRNA therapeutic indicated as an adjunct to diet to reduce triglycerides in adults with familial chylomicronemia syndrome (FCS).
Plozasiran (REDEMPLO) is an siRNA therapeutic indicated as an adjunct to diet to reduce triglycerides in adults with familial chylomicronemia syndrome (FCS).
1 associated conditions
One entry per invention. Patent families filed in the US, EP, WO and CN offices.
No patents found under this name
Patent documents usually refer to a drug by its chemical name or development code rather than its generic name, and applications are only published about 18 months after filing — so a newer drug may not appear here yet.
